This is great news folks!
Nilotinib Update: Where We Stand with a Cancer Drug for Parkinson’s
Posted by Maggie McGuire Kuhl, July 12, 2016
A promising therapy that may slow or stop Parkinson’s progression is moving forward. Today The Michael J. Fox Foundation (MJFF), the Van Andel Research Institute (VARI) in Michigan and the Cure Parkinson’s Trust (CPT) in the United Kingdom announced plans to collaborate to assess the clinical use and development of cancer drug
nilotinib.
The program includes the goal of planning of a double-blind, placebo-controlled
clinical trial of nilotinib, which MJFF hopes can begin in 2017.
Parkinson's Disease | Nilotinib Update: Where We Stand with a Cancer Drug for Parkinson’s